Business Wire

Insulet to Present Extended Real-World Evidence and Best Practices for Optimizing Care with Omnipod ® 5

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced ...
Nasdaq

Insulet (PODD) Reports Positive Study Outcomes on Omnipod 5

Insulet Corporation PODD recently presented data from pivotal studies at the American Diabetes Association Virtual 81st Scientific Sessions, concerning the treatment of type 1 diabetes in pre-school ...
Medical Device Network on MSN

FDA clears Insulet’s Omnipod 5 algorithm enhancements

Insulet has secured US Food and Drug Administration (FDA) clearance for an algorithm advancement within its Omnipod 5 ...
Morningstar

Insulet Hits Omnipod 5 Out of the Park; Raising Our Fair Value Estimate

Beyond Dash, Insulet has launched its hybrid closed-loop Omnipod 5 pump—a very compelling pump option, from our view. The pace of Insulet's innovation has quickened and has allowed the firm to come on ...
Business Wire

Insulet to Present New Clinical Data for Preschool Children and Adults using the Omnipod® 5 System

To learn more and to register for the event, scheduled for July 22, click here. The Omnipod 5 System received breakthrough device designation from the U.S. Food and Drug Administration and is ...
Seeking Alpha

From Injections to Innovation – Insulet to Present Results from a Multinational Randomized Trial of Direct Transition from Multiple Daily Injections to Omnipod® 5 in Adults ...

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced the ...
MobiHealthNews

FDA identifies Insulet Omnipod DASH battery recall as Class I

The FDA posted a notice saying the recall of Insulet's Omnipod DASH Insulin Management System Personal Diabetes Manager is a Class I, the most serious recall indicating the devices could cause serious ...
Seeking Alpha

Insulet: Omnipod 5 Driving Revenue - But Expenses Elevated

Omnipod 5 has been a major revenue catalyst for Insulet since its release. At the same time, operating expenses associated with Omnipod 5 are higher because of demand exceeding expectations. Higher ...
Nasdaq

Insulet's (PODD) Omnipod 5 Pivotal Trial Outcome Favorable

Insulet Corporation PODD recently announced positive results from the first pivotal study for the Omnipod 5 Automated Insulin Delivery System. The finding of the study suggests that Omnipod 5 ...
FierceBiotech

ADA: Insulet sets up wide-scale rollout of Omnipod 5 insulin pump

2022 is the year of the Omnipod 5 for Insulet. The year kicked off with FDA clearance for the latest generation of the insulin pump—which is tubeless, fully wearable and can be completely controlled ...
FierceBiotech

Insulet braces for $40M hit from replacing faulty remotes for Omnipod Dash insulin pumps

Insulet has begun a voluntary recall of the remote-control devices used with its Omnipod Dash insulin pumps after discovering that the devices’ batteries may be at risk of swelling, leaking or ...